Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NCT02140333 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

220

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
EGFR Mutation

Interventions

DRUG: Erlotinib

Sponsor

The First Affiliated Hospital of Guangzhou Medical University